Drug Trial Radar · NCT04299633
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
Last checked: Nov 20, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Jun 15, 2020
Primary completion
Aug 2, 2020
Study completion Sep 28, 2020
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This 3-part study will be conducted to evaluate the interaction of vadadustat with sevelamer carbonate, calcium acetate, and Auryxia in healthy male and female participants. A total of 18 participants will be enrolled in each part of the study. Part 1 of the study will be conducted to assess the effect of a single oral dose of sevelamer carbonate (1600 milligrams \[mg\]) on the pharmacokinetics (PK) of a single oral dose of vadadustat (300 mg). Part 2 of the study will be conducted to assess the effect of a single oral dose of calcium acetate (1334 mg) on the PK of a single oral dose of vadadustat (300 mg). Part 3 of the study will be conducted to assess the effect of a single oral dose of Auryxia® (2 grams) on the PK of a single oral dose of vadadustat (300 mg).
Conditions
- Healthy Volunteers
Interventions
VadadustatDrug
2 x 150 mg oral tablets
Sevelamer carbonateDrug
2 x 800 mg oral tablets
Calcium acetateDrug
2 x 667 mg oral gelcaps
Auryxia®Drug
2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vadadustat area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part
- Vadadustat area under the plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part
- Maximum observed plasma concentration (Cmax) of vadadustatTime frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Québec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.